propranolol has been researched along with Hepatorenal Syndrome in 8 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Hepatorenal Syndrome: Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.
| Excerpt | Relevance | Reference |
|---|---|---|
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "We assessed the impact of propranolol on death, risk of hepatorenal syndrome and peritonitis in patients with cirrhosis." | 3.83 | Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. ( Bang, UC; Bendtsen, F; Benfield, T; Hyldstrup, L; Jensen, JE, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mao, G | 1 |
| Li, C | 1 |
| Wang, H | 1 |
| Jv, YH | 1 |
| Zhang, Y | 1 |
| Liu, L | 1 |
| Tapper, EB | 1 |
| Parikh, ND | 1 |
| Hsu, SJ | 1 |
| Huang, HC | 1 |
| Kalambokis, GN | 1 |
| Baltayiannis, G | 1 |
| Christou, L | 1 |
| Christodoulou, D | 1 |
| Bang, UC | 1 |
| Benfield, T | 1 |
| Hyldstrup, L | 1 |
| Jensen, JE | 1 |
| Bendtsen, F | 1 |
| Angeli, P | 1 |
| Abraldes, JG | 1 |
| Tarantino, I | 1 |
| Turnes, J | 1 |
| Garcia-Pagan, JC | 1 |
| Rodés, J | 1 |
| Bosch, J | 1 |
| Duhamel, C | 1 |
| Mauillon, J | 1 |
| Berkelmans, I | 1 |
| Bourienne, A | 1 |
| Tranvouez, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study[NCT02123576] | 12 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Poor enrollment of study population) | |||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1[NCT00089570] | Phase 3 | 112 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02123576)
Timeframe: baseline and 14 days
| Intervention | g/dL (Mean) |
|---|---|
| Treatment | 0.48 |
| Placebo | 0.03 |
Defined as creatinine level above baseline value after day 7, dialysis or death (NCT02123576)
Timeframe: up to day 14
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 3 |
| Placebo | 3 |
We define as serum creatinine level decreased by >50% from baseline but not to <1.5 mg/dL, without dialysis or HRS recurrence (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 2 |
We define this as a decrease in serum creatinine level to <1.5 mg/dL without dialysis or death (NCT02123576)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Placebo | 1 |
This will be the combination of transplant free survival and those patients who received liver transplant (NCT02123576)
Timeframe: up to 1 year
| Intervention | days (Mean) |
|---|---|
| Treatment | 102 |
| Placebo | 59 |
(NCT02123576)
Timeframe: day 30 and 180
| Intervention | days (Mean) |
|---|---|
| Treatment | 80 |
| Placebo | 36 |
3 reviews available for propranolol and Hepatorenal Syndrome
| Article | Year |
|---|---|
Exploration on the Effect of Nonselective
Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; He | 2022 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
Management of ascites in patients with liver cirrhosis: recent evidence and controversies.
Topics: Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Portasystemic Shunt, T | 2013 |
5 other studies available for propranolol and Hepatorenal Syndrome
| Article | Year |
|---|---|
Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use.
Topics: Adrenergic beta-Antagonists; Ascites; Child; Esophageal and Gastric Varices; Hepatorenal Syndrome; H | 2016 |
Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers.
Topics: Aged; Cause of Death; Databases, Factual; Denmark; Dose-Response Relationship, Drug; Female; Hepator | 2016 |
β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists.
Topics: Adrenergic beta-Antagonists; Ascites; Bacterial Infections; Cardiovascular Diseases; Female; Hepator | 2011 |
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Topics: Antihypertensive Agents; Ascites; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; F | 2003 |
Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?
Topics: Adult; Aged; Digitoxin; Female; Hepatorenal Syndrome; Humans; Kidney Function Tests; Liver Cirrhosis | 2000 |